Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 08/25 05:35:19 pm
1653 GBp   -0.33%
05:20p INSIDE THE FDA : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoSm..
08/22 UK dividends lagging behind UK
08/22 UK dividends lagging behind
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2012 | 02:29pm CEST

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

James Dodwell

+ 44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
05:20p INSIDE THE FDA EBOLA EDITION : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoS..
08/24 GLAXOSMITHKLINE PAKISTAN : Board meeting of GlaxoSmithKline Pakistan Limited to ..
08/22 UK dividends lagging behind UK
08/22 UK dividends lagging behind
08/20 Cipla, godrej recognised in fortune `change the world' list
08/19 GLAXOSMITHKLINE PAKISTAN : Board meeting of GlaxoSmithKline Pakistan Limited to ..
08/19 Cipla, godrej consumer products in fortune's `change the world' list
08/18 Charles River Laboratories Announces Partnership with the Milner Therapeutics..
08/18 GlaxoSmithKline Sells Dermatology Foam Products Portfolio To Mayne
08/16 GLAXOSMITHKLINE PAKISTAN : Loss of Shares of GlaxoSmithKline Pakistan Limited
More news
Sector news : Pharmaceuticals - NEC
05:46p FTSE retreats as pharma stocks fall
03:56pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:12pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:11pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
02:15pDJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/23 10 HIV+ patients from CytoDyn's mid-stage study reach two years of complete v..
08/16 Biotechnology Dogs Move Big Pharma Off Healthcare Top Slots In August
08/16 CVRx Holds Its Nerve
08/16 Inovio Zika Phase 1 Clinical Trial Design Superior To NIH Zika Phase 1 Clinic..
08/16 ViiV Healthcare initiates late-stage development of two-drug HIV regimen
Advertisement
Financials ( GBP)
Sales 2016 26 815 M
EBIT 2016 7 264 M
Net income 2016 2 682 M
Debt 2016 13 195 M
Yield 2016 4,82%
P/E ratio 2016 35,25
P/E ratio 2017 21,83
EV / Sales 2016 3,51x
EV / Sales 2017 3,68x
Capitalization 80 848 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Average target price 17,2  GBP
Spread / Average Target 3,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Moncef Slaoui Executive Director & Chairman-Global Vaccines
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC21.19%106 869
JOHNSON & JOHNSON15.57%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.45%213 882
PFIZER INC.7.87%211 206
MERCK & CO., INC.18.76%173 462
More Results